With Nintedanib and Pirfenidone set to lose their patents in the next 3-6 years, Pliant Therapeutics moving into phase 2b, readouts expected from FibroGen's phase 3 trial and Galecto's phase 2 study and Bristol Myers Squibb's and Boehringer Ingelheim's clinical trials both well under way…the race is on to advance the next generation of IPF drugs and beat the benchmark set by the standard of care.

We're at the precipice of hailing disease-modifying IPF drugs to patients with the increasing understanding of lung pathobiology and cell cross talk using multi-omic approaches expanding the horizons of therapeutic targets to slow, halt, reverse and regenerate progressively fibrosing lung tissue. Imaging and AI are being harnessed more than ever to show therapeutic efficacy beyond lung function and clinical trials are being designed to be more effective and swifter.

The 7th IPF Summit is the undisputed, comprehensive, end-to-end, 3-day conference for you and your team to grasp the latest readouts and take new insights back to your therapeutic development. Don't miss this opportunity to discuss the latest unpublished data and network with 180+ movers and shakers in the pulmonary fibrosis field.

Read on go.evvnt.com

Continue reading at ipf-summit.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share